Obesity Drug Deal Goes Global

From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment, health-care analyst David Williamson looks at Arena Pharmaceuticals' deal with partner Eisai to market its obesity drug Belviq worldwide. Shares soared on the news, but could this really be as big of a blockbuster as it seems? David takes a look at the somewhat lackluster sales of both Arena's Belviq and competitor Vivus' Qsymia, and highlights some headwinds these companies face here, though he also notes several signs that show Eisai remains very optimistic.

Should investors be jumping in or holding off? David gives his thoughts.

More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Follow David on Twitter @MotleyDavid.

The article Obesity Drug Deal Goes Global originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story